(NASDAQ: OLMA) Olema Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 98.72%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.78%.
Olema Pharmaceuticals's revenue in 2025 is $0.On average, 10 Wall Street analysts forecast OLMA's revenue for 2026 to be $561,294,871, with the lowest OLMA revenue forecast at $0, and the highest OLMA revenue forecast at $4,044,412,764. On average, 8 Wall Street analysts forecast OLMA's revenue for 2027 to be $2,393,828,215, with the lowest OLMA revenue forecast at $1,459,298,003, and the highest OLMA revenue forecast at $3,604,645,958.
In 2028, OLMA is forecast to generate $10,033,274,548 in revenue, with the lowest revenue forecast at $5,302,193,894 and the highest revenue forecast at $16,581,371,405.